SEC Form 4 · accession 0001572426-15-000117
Nexvet Biopharma plc · NVET
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Ashraf Hanna
Director
Period of report
Sep 30, 2015
Accepted (ET)
Oct 1, 2015 · 5:09 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001618561
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Ordinary Shares | Sep 30, 2015 | M | 500 | $0.125 | A | 5,320 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Restricted Share UnitsF1 | $0.125 | Sep 30, 2015 | M | 500 | D | Sep 30, 2015 | Jul 1, 2019 | Ordinary Shares | 500 | 3,500 | D |
Explanation of responses
- F1500 of the Restricted Share Units vested and became convertible on 9/30/15, and shall vest and become convertible with respect to an additional 500 shares on each of 12/31/15, 3/31/16, 6/30/16, 9/30/16, 12/31/16, 3/31/17 and 6/30/17, in each case subject to payment of hte nominal value per share to Issuer within 30 days of vesting.